| 1. | https://www.klug-entscheiden.com/einfuehrung/konsensus-kommission-ke (last accessed on XX Xxxxxxx XXXX). |
| 2. | https://www.klug-entscheiden.com/empfehlungen/uebersicht (last accessed on XX Xxxxxxx XXXX). |
| 3. | Bhandari S, Mehta S, Khwaja A, et al.: Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med 2022; 387: 2021–32. |
| 4. | Fu EL, Evans M, Clase CM, et al.: Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol 2021; 32: 424– 35. |
| 5. | Qiao Y, Shin JI, Chen TK, et al.: Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 2020; 180: 718–26. |
| 6. | European Antimicrobial Resistance Collaborators. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. Lancet Public Health 2022; 7: e897–913. |
| 7. | Chong Y, Shimoda S, Miyake N, et al.: Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis. Infect Drug Resist 2017; 10: 193–9. |
| 8. | Vehreschild MJ, Hamprecht A, Peterson L, et al.: A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 2014; 69: 3387–92. |
| 9. | Classen AY, Henze L, von Lilienfeld-Toal M, et al.: Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021; 100: 1603–20. |
| 10. | Thorpe A, Sirota M, Juanchich M, et al.: Action bias in the public’s clinically inappropriate expectations for antibiotics. J Exp Psychol Appl 2020; 26: 422–31. |
| 11. | Cometta A, Kern WV, De Bock R, et al.: Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382–9. |
| 12. | Wu CW, Wu JY, Chen CK, et al.: Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Supportive Care Cancer 2015; 23: 2863–72. |
| 13. | Heinz WJ, Buchheidt D, Christopeit M, et al.: Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017; 96: 1775–92. |
| 14. | Hansson C, Hoborn J, Möller A, et al.: The microbial flora in venous leg ulcers without clinical signs of infection. Repeated culture using a validated standardised microbiological technique. Acta Dermato-Venereologica 1995; 75: 24–30. |
| 15. | Matkoski C, Sharp SE, Kiska DL: Evaluation of the Q score and Q234 systems for cost-effective and clinically relevant interpretation of wound cultures. J Clin Microbiol 2006; 44: 1869–72. |
| 16. | Chakraborti C, Le C, Yanofsky A: Sensitivity of superficial cultures in lower extremity wounds. J Hosp Med 2010; 5: 415–20. |
| 17. | Gardner SE, Haleem A, Jao YL, et al.: Cultures of diabetic foot ulcers without clinical signs of infection do not predict outcomes. Diabetes Care 2014; 37: 2693–701. |
| 18. | Lipsky BA, Senneville É, Abbas ZG, et al.: International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36 (Suppl 1): e3280. |
| 19. | Marchand-Senécal X, Brasg I, Kozak R, et al.: Impact of Rejection of Low-Quality Wound Swabs on Antimicrobial Prescribing: A Controlled Before-After Study. Open Forum Infect Dis 2020; 8: ofaa609. |
| 20. | Camilleri Attard F, Gatt A, Formosa C: Superficial tissue swabs versus deep tissue samples in the detection of microbiological profile of infected diabetic foot ulcerations. Int J Low Extr Wounds 2021; DOI 10.1177/15347346211053481. |
| 21. | Hindricks G, Potpara T, Dagres N, et al.: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373–498. |
| 22. | Eckardt L, Wolfes J, Frommeyer G: Benefits of early rhythm control of atrial fibrillation. Trends Cardiovasc Med 2023; 11: S1050–1738(23)00041–5. |
| 23. | Kirchhof P, Camm AJ, Goette A, et al.: Early rhythm-control therapy in patients with atrial fibrillation. N Eng J Med 2020; 383: 1305–16. |
| 24. | Willems S, Bororf K, Brandes A, et al.: Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 1219–30. |
| 25. | Eckardt L, Sehner S, Sulig A, et al.: Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J 2022; 43: 4127–414. |
| 26. | Andrade JG, Wells GA, Deyell MW, et al.: Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Eng J Med 2021; 384: 305–15. |
| 27. | Wazni OM, Dandamudi G, Sood N, et al.: Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Eng J Med 2021; 384: 316–24. |
| 28. | Borch JE, Andersen KE, Bindslev-Jensen C: The prevalence of suspected and challenge-verified penicillin allergy in a university hospital population. Basic Clin Pharmacol Toxicol 2006; 98: 357–62. |
| 29. | Shenoy ES, Macy E, Rowe T, et al.: Evaluation and Management of Penicillin Allergy: A Review. JAMA 2019; 321: 188–99. |
| 30. | Blumenthal KG, Peter JG, Trubiano JA, et al.: Antibiotic allergy. Lancet 2019; 393: 183–98. |
| 31. | West RM, Smith CJ, Pavitt SH, et al.: ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic pre- scribing and health outcomes. J Antimicrob Chemother 2019; 74: 2075–82. |
| 32. | Lee CE, Zembower TR, Fotis MA, et al.: The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160: 2819–22. |
| 33. | Blumenthal KG, Kuper K, Schulz LT, et al.: Association Between Penicillin Allergy Documentation and Antibiotic Use. JAMA Intern Med 2020; 180: 1120–2. |
| 34. | Blumenthal KG, Lu N, Zhang Y, et al.: Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ 2018; 361: k2400. |
| 35. | Macy E, Contreras R: Health care use and serious infection prevalence associated with penicillin „allergy“ in hospitalized patients: A cohort study. J Allergy Clin Immunol 2014; 133: 790–6. |
| 36. | Perez-Encinas M, Lorenzo-Martínez S, Losa-García JE, et al.: Impact of Penicillin Allergy Label on Length of Stay and Mortality in Hospitalized Patients through a Clinical Administrative National Dataset. Int Arch Allergy Immunol 2022; 183: 498–506. |
| 37. | Huang KG, Cluzet V, Hamilton K, et al.: The Impact of Reported Beta-Lactam Allergy in Hospitalized Patients With Hematologic Malignancies Requiring Antibiotics. Clin Infect Dis 2018; 67: 27–33. |
| 38. | Kaminsky LW, Ghahramani A, Hussein R, et al.: Penicillin Allergy Label Is Associated With Worse Clinical Outcomes in Bacterial Pneumonia. J Allergy Clin Immunol Pract 2022;10: 3262–9. |
| 39. | S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus.AWMF-Registernummer 092/001 – update 2018. https://register.awmf.org/de/leitlinien/detail/092–001 (last accessed on 26 April 2023). |
| 40. | Trubiano JA, Vogrin S, Chua KYL, et al.: Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Internal Medicine 2020;180: 745–52. |
| 41. | Copaescu AM, Vogrin S, James F, et al.: Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med 2023; 183: 944–52. |
| 42. | Piotin A, Godet J, Trubiano A, et al.: Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol 2022; 128: 27–32. |
| 43. | Koch T, Leubner H, Brehm T, Witte J: Penicillinallergie: Sicher und effektiv ausschließen. Dtsch Arztebl 2023; 120: A-822/B-699. |
| 44. | Rinella ME, Lazarus JV, Ratziu V, et al.: A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78: 1966–86. |
| 45. | Ward ZJ, Bleich SN, Cradock AL, et al.: Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med 2019; 381: 2440–50. |
| 46. | Estes C, Razavi H, Loomba R, et al.: Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67: 123–33. |
| 47. | Huang DQ, Wilson LA, Behling C, et al.: Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology 2023; 165: 463–72.e5. |
| 48. | Koutoukidis DA, Koshiaris C, Henry JA, et al.: The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021; 115: 1544–55. |
| 49. | Roeb E, Canbay A, Bantel H, et al.: Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) April 2022 – AWMF-Registernummer: 021-025. |
| 50. | Hannah WN Jr, Harrison SA: Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016; 20: 339–50. |
| 51. | Hall KD, Ayuketah A, Brychta R, et al.: Ultra-Processed Diets Cause Excess Calorie Intake and Weight Gain: An Inpatient Randomized Controlled Trial of Ad Libitum Food Intake. Cell Metab 2019; 30: 67–77.e3. Erratum in: Cell Metab 2019; 30: 226 and Cell Metab 2020; 32: 690. |
| 52. | Vancells Lujan P, Viñas Esmel E, Sacanella Meseguer E: Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. Nutrients 2021; 13: 1442. |
| 53. | Malik VS, Hu FB: The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. Nat Rev Endocrinol 2022; 18: 205–18. |
| 54. | Newsome PN, Buchholtz K, Cusi K, et al.: A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med 2021; 384: 1113–24. |
| 55. | Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.: Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367–78.e5. |
| 56. | Promrat K, Kleiner DE, Niemeier HM, et al.: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121–129. |
| 57. | Keating SE, Hackett DA, George J, et al.: Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157–66. |
| 58. | Johnson NA, Sachinwalla T, Walton DW, et al.: Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105–12. |
| 59. | Hashida R, Kawaguchi T, Bekki M, et al.: Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 2017; 66: 142–52. |
| 60. | Fernández T, Viñuela M, Vidal C, et al.: Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One 2022; 17: e0263931. |
| 61. | Verrastro O, Panunzi S, Castagneto-Gissey L, et al.: Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401: 1786–97. |
Klug entscheiden in der Nephrologie
Literaturnachweise 2024
Literaturnachweise
- KDIGO: 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1–150.
- Hasegawa T, Bragg-Gresham JL, Yamazaki S, et al.: Greater first-year survival on hemodialysis in facilities in which patients are provided earlier and more frequent pre-nephrology visits. Clin J Am Soc Nephrol 2009; 4: 595–602.
- Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A: The Prevalence of Renal Failure. Dtsch Arztebl Int 2016; 113(6): 85–91.
- Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, et al.: Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3: 514–25.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461–70.
- Levey AS, Stevens LA, Schmid CH, et al.: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–12.
- Levin A, Bakris GL, Molitch M, et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–8.
- Moranne O, Froissart M, Rossert J, et al.: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20: 164–71.
- Vassalotti JA, Uribarri J, Chen SC, et al.: Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008; 51: S56–S68.
- Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770–9.
- Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555–62.
- Newhouse JH, Kho D, Rao QA, Starren J: Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191: 376–82.
- Cely CM, Schein RM, Quartin AA: Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study. Crit Care 2012; 16: R67.
- Baumgarten DA, Ellis JH: Contrast-induc - ed nephropathy: contrast material not required? AJR Am J Roentgenol 2008; 191: 383–6.
- Katzberg RW, Newhouse JH: Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010; 256: 21–8.
- Davenport MS, Cohan RH, Ellis JH: Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. AJR Am J Roentgenol. 2015; 204: 1174–81.
- Thomsen HS, Stacul F: CIN: can we forget it? Acta Radiol 2014; 55: 1027–30.
- Kausz A, Pahari D: The value of vaccination in chronic kidney disease. Semin Dial 2004; 17: 9–11.
- Wiese-Posselt M, Tertilt C, Zepp F: Vaccination recommendations for Germany. Dtsch Arztebl Int 2011; 108(45): 771–80.
- National Kidney Foundation: A guide for adults with chronic kidney disease or kidney failure living on dialysis or with a kidney transplantguide for adults with chronic kidney disease or kidney failure living on dialysis or with a kidney transplant. www kidney org/atoz/content/ vaccinations. 2016.
- KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1–155.
- Palmer SC, Wong G, Iff S, et al.: Fluid in - take and all-cause mortality, cardiovascular mortality and kidney function: a population- based longitudinal cohort study. Nephrol Dial Transplant 2014; 29: 1377–84.
- Grams ME, Estrella MM, Coresh J, Brower RG, Liu KD: Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6: 966–73.
- Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL: A positive fluid balance is associated with a worse out - come in patients with acute renal failure. Crit Care 2008; 12: R74.
- Bouchard J, Soroko SB, Chertow GM, et al.: Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76: 422–7.
- Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL: High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44: 402–9.
- Ho KM, Power BM: Benefits and risks of furosemide in acute kidney injury. Anaesthesia 2010; 65: 283–93.
- Kellum JA, Lameire N: Diagnosis, evalu - ation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17: 204.
- Wheatley K, Ives N, Gray R, et al.: Revascularization versus medical therapy for renal- artery stenosis. N Engl J Med 2009; 361: 1953–62.
- 30. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, et al.: Stenting and medical therapy for atherosclerotic renalartery stenosis. N Engl J Med 2014; 370: 13–22.
- Ritchie J, Alderson HV, Kalra PA: Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials. Curr Opin Nephrol Hypertens 2014; 23: 525–32.
- Rahman S, Malcoun A: Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. Prim Care 2014; 41: 803–21.
- Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H: Initiation of antihypertensive treatment during nonstero - idal anti-inflammatory drug therapy. JAMA 1994; 272: 781–6.